Derick Holt
Pediatric Ophthalmology and Strabismus Specialist · Fresno, CANPI 1386886729
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novartis at 28.6% of the total.
Across 33 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$182
- Bausch & Lomb, A Division Of Bausch Health US, LLC$139
- AbbVie$99
- Amgen$62
- Biotissue Holdings Inc.$57
- Alcon$37
- plus $61 from 3 others
What the payments were for
- Food & beverage$636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $182 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $139 |
| AbbVie | 3 | $99 |
| Amgen | 3 | $62 |
| Biotissue Holdings Inc. | 2 | $57 |
| Alcon | 2 | $37 |
| Dompe US, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 2 | $16 |
How this compares
$636 in reported general payments places this provider in the 55th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.
See all pediatric ophthalmology and strabismus specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $124 |
Paid to pharmacies, not to this prescriber.
Other pediatric ophthalmology and strabismus specialist in Fresno
- Scott LambertPalo Alto$20K
- Donny SuhIrvine$14K
- Leila KhazaeniLoma Linda$9K
- Euna KooPalo Alto$6K
- Mark SilverbergSanta Barbara$5K
- Jennifer DunbarSan Bernardino$5K
- Shira RobbinsSan Diego$5K
- Mona FayadLos Angeles$3K
- Douglas FredrickDaly City$2K
- Ann ShueStanford$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.